Australia has already spent hundreds of millions over the past 36 months after raising the prices of 950 PBS medicines in 2022 to secure supply in a challenging global environment. If global pressure now forces higher prices for other medicines, so be it, but of course, it would be just another stop-gap solution for a system built on a terrible patient-loathing law. …
Australia can increase prices in response to pressure, as it did just 36 months ago for 950 medicines
December 2, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News